Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
PaperCitations, authors & open-access status
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,434 citations, 2015 year and closed oa status.
1,434
Citations
2015
Year
closed
OA Status